Zurich, Switzerland, November 16, 2022 – MUVON Therapeutics announces the appointment of Dr Branimir Brankov to its Board of Directors and Professor Christopher Chapple to its Scientific Advisory Board, effective immediately.
Muvon Therapeutics announces the addition of Branimir Brankov MD MBA PhD to its Board of Directors.
Chairman of the Board of Directors Christian Jaeggi noted “Dr Brankov is a seasoned professional business development global leader with significant transaction experience as we enter a critical stage at MUVON Therapeutics. He has the reputation, network and skill set required for strategic transactions as the interest in our development pipeline grows from leading pharma and major investment institutions.”
Dr Brankov is an experienced Senior Executive with extensive pharmaceutical industry experience, formerly at Merck & Co Headquarters in the US, Europe and rest of the world. He served in many leadership roles of growing importance. Among them - Head of Strategic Business Intelligence and Head of Business Development in Corporate development, and Managing Director for many countries and regions at Merck &Co inc.
Dr Brankov is the co-founder and CEO of Clover Key Bioscience and Senior Consultant at Princeton Capital Advisors, USA and Azierta, Spain.
Dr Brankov graduated with a Medical Doctor degree from Medical Academy, Sofia Bulgaria and specialized as a neurosurgeon. He also has an MBA with specialization in marketing from Rutgers University, USA, a PhD from Medical University, Varna, and a specialization in marketing as part of Merck’s Future Leaders Program at Harvard University.
CEO Deana Mohr welcomes Professor Christopher Chapple to the Scientific Advisory Board.
Deana Mohr notes “As we reported our successful Phase I study recently at the International Continence Society in Vienna and began enrollment for Phase II, we decided to expand the bench of scientific rigor inviting distinguished academic researchers and clinicians like Professor Chapple to join us. We are honored to have the benefit of his outstanding experience and insight. As with all of our Scientific Advisors, Prof Chapple has no position within the Company or financial interest.”
Professor Chapple is a Consultant Urological Surgeon at Sheffield Teaching Hospitals, Honorary Professor at University of Sheffield and Visiting Professor at Sheffield Hallam University. He has a particular interest in the functional reconstruction of the lower urinary tract and the underlying pharmacological control mechanisms and provides a tertiary service in lower urinary tract reconstructive surgery. He trained at the Middlesex Hospital where he completed his doctorate thesis. He continued at the Institute of Urology in London for his sub-specialist training. He is Secretary General of the European Association of Urology, having previously been Chairman of the International Relations Committee, Adjunct Secretary General Responsible for Education, and Director of the European School of Urology. He was the Network Coordinator for the European Reference Network (ERN) for rare urogenital diseases and complex conditions (eUROGEN) from 2016-2019.
He was the editor-in-chief of the journal Neuro-urology & Urodynamics from 2006-2016 and is on the editorial board of several international journals. He is an active member of many urological associations and societies including the British Association of Urological Surgeons, the European Association of Urology, the International Continence Society, the Association of Academic European Urologists and the American Association of Genitourinary Surgeons. He has chaired a number of guidelines initiatives including the NICE GDG on Male LUTS and the ICUD Consultation on Male LUTS. BAUS awarded him the St Peter’s medal 2011, SUFU awarded him the Lifetime Achievement Award in 2015, and the International Continence Society made him the inaugural member of their Hall of Fame in 2020.
Prof. Chapple has co-authored over 850 articles, comments and letters in peer-reviewed journals, and has written several chapters and books.